Shanghai, China
HuidaGene Therapeutics is a dynamic player in the biotech industry, established in 2018 and headquartered in China, with operations also in New Jersey. The company is at the forefront of genomic medicine, pioneering CRISPR-based gene-editing tools that promise transformative treatments for conditions affecting the ophthalmological, otological, myological, and neurological fields.
With its slogan, "辉大，给患者回答 | Answering the Patients！", HuidaGene is addressing global healthcare needs through a robust pipeline of preclinical therapeutic programs. The focus is on potentially curative treatments for life-threatening conditions by specifically targeting and repairing genetic defects.
Having secured a Series C investment round on May 12, 2022, led by renowned investors such as Kunlun Capital, CD Capital, and Sherpa Healthcare Partners, the company is well-positioned for growth in the competitive sectors of Biopharma and Biotechnology. Its innovative approach holds significant promise for the future of life sciences and healthcare.
